Sun Pharmaceutical Industries announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis. �ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-to severe plaque psoriasis,� said Kirti Ganorkar, Managing Director, Sun Pharma. �We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines. Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years.�ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis. Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data shows that ILUMYA is a sustainable choice for patients over the long term.Powered by Capital Market - Live News

Net profit of Sun Pharmaceutical Industries rose 2.56% to Rs 3117.95 crore in the quarter ended September 2025 as against Rs 3040.16 crore during the previous quarter ended September 2024. Sales rose 8.60% to Rs 14405.22 crore in the quarter ended September 2025 as against Rs 13264.22 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales14405.2213264.22 9 OPM %31.4329.70 - PBDT4897.114223.79 16 PBT4167.613597.88 16 NP3117.953040.16 3 Powered by Capital Market - Live News

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 5 November 2025.Powered by Capital Market - Live News

Net profit of Sun Pharmaceutical Industries declined 19.64% to Rs 2278.63 crore in the quarter ended June 2025 as against Rs 2835.62 crore during the previous quarter ended June 2024. Sales rose 10.07% to Rs 13786.07 crore in the quarter ended June 2025 as against Rs 12524.51 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales13786.0712524.51 10 OPM %31.2028.80 - PBDT4691.324078.63 15 PBT3990.773423.50 17 NP2278.632835.62 -20 Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced top-line results from two Phase 3 clinical studies evaluating the efficacy and safety of tildrakizumab 100 mg (ILUMYA�) administered over 24 weeks for treatment of active psoriatic arthritis. Treatment with tildrakizumab 100 mg (ILUMYA) resulted in greater improvements in PsA signs and symptoms at Week 24 compared to treatment with placebo. Both the INSPIRE-1 and INSPIRE-2 studies achieved the primary endpoint, with a higher proportion of patients in the INSPIRE-1 and INSPIRE-2 studies treated with tildrakizumab achieving ACR20 responses at week 24, compared to those receiving placebo (p < 0.05). We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future,� said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma.Powered by Capital Market - Live News